From billion-euro megadeals to targeted niche investments, Europe’s mRNA landscape is surging. BioNTech’s $1.25B acquisition of CureVac and Cipla’s €3M boost for Ethris GmbH are reshaping the competitive and therapeutic landscape. These landmark moves set the stage for critical conversations in this session on how strategic capital and collaboration can unlock the next wave of mRNA innovation